Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing

BMC Medical Genomics

Volumn 7, Issue 1, 2014, Pages

  Wong, Stephen Q ^a   Li, Jason ^a   Tan, Angela Y C ^a   Vedururu, Ravikiran ^a   Pang, Jia Min B ^a,b   Do, Hongdo ^c   Ellul, Jason ^a   Doig, Ken ^a   Bell, Anthony ^a   Macarthur, Grant A ^a,b   Fox, Stephen B ^a,b   Thomas, David M ^a,b,d   Fellowes, Andrew ^a   Parisot, John P ^a,b   Dobrovic, Alexander ^a,b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

URACIL DNA GLYCOSIDASE;

ARTICLE; AUSTRALIA; BONE CANCER; BRAIN CANCER; BREAST CANCER; CANCER GENETICS; CANCER OF UNKNOWN PRIMARY SITE; CANCER REGISTRY; CLINICAL PROTOCOL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA EXTRACTION; DNA FRAGMENTATION; ESOPHAGUS CANCER; FEASIBILITY STUDY; FEMALE; GENE FREQUENCY; GENETIC ALGORITHM; GENETIC PROCEDURES; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CANCER; LONGITUDINAL STUDY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MASSIVELY PARALLEL SEQUENCING; MELANOMA; MICROFLUIDICS; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; SOFT TISSUE CANCER; UTERINE CERVIX CANCER;

ARTIFACTS; CELL LINE, TUMOR; DNA FRAGMENTATION; FALSE POSITIVE REACTIONS; FORMALDEHYDE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; NEOPLASMS; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; TEMPLATES, GENETIC; TISSUE FIXATION; URACIL-DNA GLYCOSIDASE;

EID: 84901604272     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-7-23     Document Type: Article

References (31)

1. Profiling critical cancer gene mutations in clinical tumor samples. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, Fiorentino M, Rubin MA, Polyak K, Chan J, Wang Y, Fletcher JA, Santagata S, Corso G, Roviello F, Shivdasani R, Kieran MW, Ligon KL, Stiles CD, Hahn WC, Meyerson ML, et al. PloS one 2009 4 7887 10.1371/journal.pone.0007887 19924296
2. Clinical implications of the cancer genome. Macconaill LE, Garraway LA, J Clin Oncol 2010 28 35 5219 5228 10.1200/JCO.2009.27.4944 20975063
3. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Mar VJ, Wong SQ, Li J, Scolyer RA, McLean C, Papenfuss AT, Tothill RW, Kakavand H, Mann GJ, Thompson JF, Behren A, Cebon JS, Wolfe R, Kelly JW, Dobrovic A, McArthur GA, Clin Cancer Res 2013 19 4589 4598 10.1158/1078-0432.CCR-13-0398 23833303
4. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, Ducar M, Van Hummelen P, Macconaill LE, Hahn WC, Meyerson M, Gabriel SB, Garraway LA, Cancer discovery 2012 2 1 82 93 10.1158/2159-8290.CD-11-0184 22585170
5. Use of formalin-fixed and paraffin-embedded tissues for diagnosis and therapy in routine clinical settings. Berg D, Malinowsky K, Reischauer B, Wolff C, Becker KF, Methods Mol Biol 2011 785 109 122 10.1007/978-1-61779-286-1-8 21901596
6. The isolation of nucleic acids from fixed, paraffin-embedded tissues-which methods are useful when? Gilbert MT, Haselkorn T, Bunce M, Sanchez JJ, Lucas SB, Jewell LD, Van Marck E, Worobey M, PLoS One 2007 2 6 537 10.1371/journal.pone.0000537 17579711
7. DNA damage reduces Taq DNA polymerase fidelity and PCR amplification efficiency. Sikorsky JA, Primerano DA, Fenger TW, Denvir J, Biochem Biophys Res Commun 2007 355 2 431 437 10.1016/j.bbrc.2007.01.169 17303074 (Pubitemid 46282646)
8. Heat-induced formation of reactive oxygen species and 8-oxoguanine, a biomarker of damage to DNA. Bruskov VI, Malakhova LV, Masalimov ZK, Chernikov AV, Nucleic Acids Res 2002 30 6 1354 1363 10.1093/nar/30.6.1354 11884633 (Pubitemid 34679713)
9. Mutations induced by ultraviolet light. Pfeifer GP, You YH, Besaratinia A, Mutat Res 2005 571 1-2 19 31 15748635 (Pubitemid 40313429)
10. Instability and decay of the primary structure of DNA. Lindahl T, Nature 1993 362 6422 709 715 10.1038/362709a0 8469282 (Pubitemid 23125973)
11. Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase. Do H, Dobrovic A, Oncotarget 2012 3 5 546 558 22643842
12. Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates. Do H, Wong SQ, Li J, Dobrovic A, Clin Chem 2013 59 9 1376 1383 10.1373/clinchem.2012.202390 23649127
13. DNA sequences from multiple amplifications reveal artifacts induced by cytosine deamination in ancient DNA. Hofreiter M, Jaenicke V, Serre D, von Haeseler A, Paabo S, Nucleic Acids Res 2001 29 23 4793 4799 10.1093/nar/29.23. 4793 11726688 (Pubitemid 33133550)
14. Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies. Do H, Dobrovic A, Mol Canc 2009 8 82 10.1186/1476-4598-8-82
15. Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. Kerick M, Isau M, Timmermann B, Sultmann H, Herwig R, Krobitsch S, Schaefer G, Verdorfer I, Bartsch G, Klocker H, Lehrach H, Schweiger MR, BMC Med Genomics 2011 4 68 10.1186/1755-8794-4-68 21958464
16. Identification of high-confidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimens. Yost SE, Smith EN, Schwab RB, Bao L, Jung H, Wang X, Voest E, Pierce JP, Messer K, Parker BA, Harismendy O, Frazer KA, Nucleic Acids Res 2012 40 14 107 10.1093/nar/gks299 22492626
17. Detection of ultra-rare mutations by next-generation sequencing. Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA, Proc Natl Acad Sci U S A 2012 109 36 14508 14513 10.1073/pnas.1208715109 22853953
18. Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens. Spencer DH, Sehn JK, Abel HJ, Watson MA, Pfeifer JD, Duncavage EJ, J Mol Diagn 2013 15 5 623 633 10.1016/j.jmoldx.2013.05.004 23810758
19. Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors. Anaka M, Hudson C, Lo PH, Do H, Caballero OL, Davis ID, Dobrovic A, Cebon J, Behren A, BMC Med Genomics 2013 6 40 10.1186/1755-8794-6-40 24119551
20. Genome-wide massively parallel sequencing of formaldehyde fixed-paraffin embedded (FFPE) tumor tissues for copy-number- and mutation-analysis. Schweiger MR, Kerick M, Timmermann B, Albrecht MW, Borodina T, Parkhomchuk D, Zatloukal K, Lehrach H, PLoS One 2009 4 5 5548 10.1371/journal.pone.0005548 19440246
21. PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups. Cizkova M, Susini A, Vacher S, Cizeron-Clairac G, Andrieu C, Driouch K, Fourme E, Lidereau R, Bieche I, Breast Cancer Res 2012 14 1 28 10.1186/bcr3113 22330809
22. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R, J Clin Oncol 2012 30 8 777 782 10.1200/JCO.2011.36.1196 22271473
23. Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Bullock M, O'Neill C, Chou A, Clarkson A, Dodds T, Toon C, Sywak M, Sidhu SB, Delbridge LW, Robinson BG, Learoyd DL, Capper D, von Deimling A, Clifton-Bligh RJ, Gill AJ, Endocr Relat Cancer 2012 19 779 784 10.1530/ERC-12-0239 22997209
24. A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Diaz-Padilla I, Hirte H, Oza AM, Clarke BA, Cohen B, Reedjik M, Zhang T, Kamel-Reid S, Ivy SP, Hotte SJ, Razak AA, Chen EX, Brana I, Wizemann M, Wang L, Siu LL, Bedard PL, Invest New Drugs 2013 31 5 1182 1191 10.1007/s10637-013-0001-5 23860641
25. EGFR mutation analysis in sputum of lung cancer patients: a multitechnique study. Hubers AJ, Heideman DA, Yatabe Y, Wood MD, Tull J, Taron M, Molina MA, Mayo C, Bertran-Alamillo J, Herder GJ, Koning R, Sie D, Lung Cancer 2013 82 1 38 43 10.1016/j.lungcan.2013.07.011 23927883
26. Individualized Systems Medicine (ISM) strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, Almusa H, Bespalov MM, Ellonen P, Elonen E, Gjertsen BT, Karjalainen R, Kulesskiy E, Lagstrom S, Lehto A, Lepisto M, Lundan T, Majumder MM, Lopez Marti JM, Mattila P, Murumagi A, Mustjoki S, Palva A, Parsons A, Pirttinen T, Ramet ME, Suvela M, Turunen L, Vastrik I, Wolf M, et al. Canc Discov 2013 3 12 1416 4129 10.1158/2159-8290.CD-13-0350
27. Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsies. Sah S, Chen L, Houghton J, Kemppainen J, Marko AC, Zeigler R, Latham GJ, Genome Med 2013 5 8 77 10.1186/gm481 24001039
28. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Devitt B, Liu W, Salemi R, Wolfe R, Kelly J, Tzen CY, Dobrovic A, McArthur G, Pigment Cell Melanoma Res 2011 24 4 666 672 10.1111/j.1755-148X.2011.00873.x 21615881
29. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R, Lancet Oncol 2013 14 249 256 10.1016/S1470-2045(13)70024-X 23414587
30. Targeting NRAS in melanoma. Kelleher FC, McArthur GA, Cancer J 2012 18 2 132 136 10.1097/PPO.0b013e31824ba4df 22453013
31. Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours. Wong SQ, Li J, Salemi R, Sheppard KE, Hongdo D, Tothill RW, McArthur GA, Dobrovic A, Sci Rep 2013 3 3494 24336498